Skip to main content

Table 1 Demographic and baseline characteristics

From: Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

  MET + SU
N = 4655
MET + DPP-4i
N = 2899
MET + SGLT-2i
N = 441
Other*
N = 1102
Overall
N = 9097
Male, n (%) 2679 (57.6) 1704 (58.8) 266 (60.3) 551 (50.0) 5200 (57.2)
Age (years), mean (SD) 61.54 (12.97) 60.81 (12.34) 55.05 (10.14) 62.81 (14.85) 61.15 (12.98)
  <50 892 (19.2%) 544 (18.8%) 128 (29.0%) 210 (19.1%) 1774 (19.5%)
 50 to <60 1150 (24.7%) 805 (27.8%) 165 (37.4%) 241 (21.9%) 2361 (26.0%)
 60 to <70 1291 (27.7%) 842 (29.0%) 119 (27.0%) 275 (25.0%) 2527 (27.8%)
 ≥70 1322 (28.4%) 708 (24.4%) 29 (6.6%) 376 (34.1%) 2435 (26.8%)
HbA1c (%), mean (SD) 9.19 (1.88) 8.75 (1.50) 9.07 (1.58) 8.72 (1.91) 8.98 (1.77)
 <7 283 (6.2%) 147 (5.1%) 20 (4.6%) 164 (15.2%) 614 (6.9%)
 7 to <8 971 (21.3%) 829 (28.8%) 100 (23.0%) 276 (25.5%) 2176 (24.3%)
 8 to <9 1245 (27.3%) 923 (32.1%) 120 (27.7%) 254 (23.5%) 2542 (28.4%)
 9 to <10 783 (17.2%) 468 (16.3%) 84 (19.4%) 152 (14.1%) 1487 (16.6%)
 10 to <11 491 (10.8%) 244 (8.5%) 54 (12.4%) 92 (8.5%) 881 (9.8%)
 ≥11 787 (17.3%) 266 (9.3%) 56 (12.9%) 144 (13.3%) 1253 (14.0%)
HbA1c (mmol/mol), mean (SD) 77 (20.6) 72 (16.4) 76 (17.3) 72 (20.9) 75 (19.3)
BMI (kg/m2, mean (SD) 31.78 (6.50) 33.21 (6.56) 36.56 (6.98) 33.12 (7.93) 32.64 (6.82)
 <20 43 (0.9%) 8 (0.3%) 0 24 (2.2%) 75 (0.8%)
 20 to <25 498 (10.9%) 194 (6.8%) 8 (1.8%) 106 (9.8%) 806 (9.0%)
 25 to <30 1457 (31.9%) 795 (27.7%) 65 (14.8%) 273 (25.2%) 2590 (28.9%)
 30 to <35 1366 (29.9%) 887 (31.0%) 129 (29.5%) 301 (27.8%) 2683 (30.0%)
 ≥35 1208 (26.4%) 982 (34.3%) 236 (53.9%) 379 (35.0%) 2805 (31.3%)
Weight (kg), mean (SD) 90.97 (21.00) 96.00 (21.50) 107.30 (22.87) 93.63 (25.55) 93.70 (22.18)
 <60 189 (4.1%) 63 (2.2%) 2 (0.5%) 51 (4.7%) 305 (3.4%)
 60 to <80 1227 (26.6%) 578 (20.1%) 40 (9.1%) 298 (27.3%) 2143 (23.8%)
 80 to <100 1837 (39.9%) 1133 (39.3%) 127 (28.9%) 361 (33.1%) 3458 (38.4%)
 100 to <120 954 (20.7%) 728 (25.3%) 166 (37.7%) 232 (21.3%) 2080 (23.1%)
 ≥120 399 (8.7%) 378 (13.1%) 105 (23.9%) 149 (13.7%) 1031 (11.4%)
Time since diagnosis (years), median (IQR) 4.00 (1.57–7.20) 4.25 (1.88–7.21) 3.30 (1.47–5.55) 4.64 (1.94–8.05) 4.10 (1.70–7.22)
 <6 months 542 (11.6%) 237 (8.2%) 40 (9.1%) 74 (6.7%) 893 (9.8%)
 6 months to <1 year 283 (6.1%) 174 (6.0%) 35 (7.9%) 68 (6.2%) 560 (6.2%)
 1 to <3 years 1076 (23.1%) 658 (22.7%) 129 (29.3%) 250 (22.7%) 2113 (23.2%)
 3 to <5 years 839 (18.0%) 591 (20.4%) 104 (23.6%) 194 (17.6%) 1728 (19.0%)
 ≥5 years 1915 (41.1%) 1239 (42.7%) 133 (30.2%) 516 (46.8%) 3803 (41.8%)
Time since initiation of first-line therapy (years), median (IQR) 2.20 (0.72–4.65) 2.62 (1.02–4.89) 2.05 (0.85–4.02) 2.30 (0.89–4.84) 2.33 (0.85–4.72)
  <6 months 953 (20.5%) 427 (14.7%) 71 (16.1%) 171 (15.5%) 1622 (17.8%)
 6 months to <1 year 474 (10.2%) 280 (9.7%) 50 (11.3%) 124 (11.3%) 928 (10.2%)
 1 to <3 years 1346 (28.9%) 884 (30.5%) 157 (35.6%) 346 (31.4%) 2733 (30.0%)
 3 to <5 years 840 (18.1%) 613 (21.2%) 89 (20.2%) 199 (18.1%) 1741 (19.1%)
 ≥5 years 1042 (22.4%) 695 (24.0%) 74 (16.8%) 262 (23.8%) 2073 (22.8%)
  1. BMI body mass index, DPP-4i dipeptidyl peptidase-4 inhibitor, HbA1c glycated haemoglobin, IQR interquartile range, MET metformin, SD standard deviation, SGLT-2i sodium–glucose cotransporter 2 inhibitor, SU sulfonylurea
  2. *Includes all other add-on combinations to metformin, combinations without metformin and other monotherapies
  3. Baseline HbA1c, BMI and weight were missing for 144, 138 and 80 patients, respectively